论文部分内容阅读
观察预防性应用凉膈散对放射性肺炎患者血清中转化生长因子-β1(TGF-β1)、白介素6(IL-6)的影响。依据纳入、排除标准纳入自2014年至2016年就诊于我院确诊肺癌放疗患者126例,随机分为治疗组(采用凉膈散+放射治疗),对照组(单纯放疗组),每组63例,随访时间6个月。检测两组患者放射治疗前、后血清中转化生长因子-β1(TGF-β1)、白介素6(IL-6),通过询问临床症状,复查肺功能、胸部CT检查对已发生放射性肺炎的患者按RTOG标准进行分级。共完成临床研究患者126,基线资料无明显差异(P﹥0.05)。治疗组放射性肺炎共发生10例:2级6例,3级4例,发生率为15.9%(10/63);治疗组共20例:2级8例,3级10例,4级2例,发生率31.7%(20/63)。两组比较差异有统计学意义(P﹤0.05),治疗组前后血清中TGF-β1,治疗后较治疗前下降;对照组,治疗后较治疗前明显升高。经t检验,两组治疗前后血清中TGF-β1均有统计学意义(P﹤0.05),治疗组前后血清IL-6治疗后较治疗前轻度升高,前后比较无统计学差异(P﹥0.05);对照组治疗后较治疗前明显升高,前后比较有统计学差异(P﹤0.01)。凉膈散明显降低放疗患者血清中IL-6、TGF-β1表达水平,降低机体炎症反应;明显降低接受放疗肺癌患者放射性肺炎的发生率。
To observe the effect of prophylactic application of Liangge San on the serum levels of TGF-β1 and IL-6 in patients with radiation pneumonia. According to the inclusion and exclusion criteria included 126 cases of lung cancer patients diagnosed with lung cancer from 2014 to 2016. They were randomly divided into treatment group (treated with radiotherapy plus radiotherapy) and control group (radiotherapy alone group), with 63 patients in each group , Followed up for 6 months. The serum TGF-β1 (TGF-β1) and interleukin-6 (IL-6) levels were measured before and after radiotherapy in both groups. The patients with radiation pneumonitis were examined by examining the clinical symptoms, RTOG standard for grading. A total of 126 patients completed the clinical study, there was no significant difference in baseline data (P> 0.05). There were 10 cases of radiation pneumonitis in the treatment group: 6 in grade 2 and 4 in grade 3, the incidence rate was 15.9% (10/63). There were 20 cases in the treatment group: 8 cases in stage 2, 10 cases in stage 3 and 2 cases in stage 4 , The incidence of 31.7% (20/63). The difference between the two groups was statistically significant (P <0.05). The levels of TGF-β1 in the serum before and after treatment in the treatment group were significantly lower than those before treatment, while those in the control group were significantly higher than those before treatment. The levels of TGF-β1 in both groups before and after treatment were significantly higher than those before treatment (P <0.05). The levels of serum IL-6 before and after treatment in the two groups were slightly increased before and after treatment, and there was no significant difference between before and after treatment (P> 0.05). The control group after treatment was significantly higher than before treatment, before and after a statistically significant difference (P <0.01). Liangge powder significantly reduces the serum IL-6, TGF-β1 expression in patients with radiotherapy, reduce the body’s inflammatory response; significantly reduce the incidence of radiation pneumonitis in patients receiving radiotherapy lung cancer.